263 related articles for article (PubMed ID: 20001867)
1. Bevacizumab for advanced breast cancer.
Goldfarb SB; Traina TA; Dickler MN
Womens Health (Lond); 2010 Jan; 6(1):17-25. PubMed ID: 20001867
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of metastatic breast cancer.
Traina TA
Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
[TBL] [Abstract][Full Text] [Related]
3. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
[TBL] [Abstract][Full Text] [Related]
4. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
8. The role of angiogenesis inhibition in the treatment of breast cancer.
Sledge GW; Rugo HS; Burstein HJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2. PubMed ID: 17139244
[TBL] [Abstract][Full Text] [Related]
9. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: pros and cons.
Sini V; Cassano A; Corsi D; De Laurentiis M; Gamucci T; Mauri M; Naso G; Roselli M; Ruggeri EM; Tonini G; Vici P; Zampa G; Marchetti P
Tumori; 2016 Oct; 102(5):472-480. PubMed ID: 27647231
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
15. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
16. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
[No Abstract] [Full Text] [Related]
17. Acute lung injury associated with docetaxel and bevacizumab.
Prat A; Martínez P; Serrano C; Montero MA; Andreu J; Cortés J
Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):803-5. PubMed ID: 17889516
[No Abstract] [Full Text] [Related]
18. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
Schwartzberg LS; Badarinath S; Keaton MR; Childs BH
Clin Breast Cancer; 2014 Jun; 14(3):161-8. PubMed ID: 24566467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]